BETR — BetterLife Pharma Income Statement
0.000.00%
- CA$9.87m
- CA$13.80m
Annual income statement for BetterLife Pharma, fiscal year end - January 31st, CAD millions except per share, conversion factor applied.
2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | 2025 January 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0 | 0 | — | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 20.2 | 10.7 | 9.4 | 2.64 | 4.33 |
| Operating Profit | -20.2 | -10.7 | -9.4 | -2.64 | -4.33 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -36.4 | -12 | -9.37 | -2.9 | -3.62 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -36.4 | -12.2 | -9.37 | -2.9 | -3.62 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -36.4 | -12.2 | -9.02 | -2.89 | -3.52 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -36.4 | -12.2 | -9.02 | -2.89 | -3.52 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.305 | -0.158 | -0.105 | -0.032 | -0.034 |